SHP001
MISSION® Lentiviral Packaging Mix
Production of replication incompetent viral particles
Synonym(s):
Lentiviral Packaging, Lentiviral Packaging Kit
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
41106609
NACRES:
NA.51
Related Categories
General description
The MISSION® shRNA product line is centered on a transfer vector-based RNAi library against annotated mouse and human genes that can be used in conjunction with this Lentiviral Packaging Mix. In this packaging system, the pseudo-typing with VSV-G broadens the viral tropism associated with the virus. Therefore, these lentiviral particles can efficiently deliver the transfer sequence of interest to a wide variety of cell types, including primary and non-dividing cells.
The MISSION® Lentiviral Packaging Mix is an optimized formulation of two plasmids expressing the key HIV packaging genes and a heterologous viral envelope gene.
Lentiviral particles are generated from three main components:
The Lentiviral Packaging Mix contains the first two components; it is designed to be co-transfected along with a compatible lentiviral transfer vector in order to create high-titer pseudo-typed lentiviral particles used for downstream transduction applications.
The MISSION® Lentiviral Packaging Mix is an optimized formulation of two plasmids expressing the key HIV packaging genes and a heterologous viral envelope gene.
Lentiviral particles are generated from three main components:
- The packaging vector, which contains the minimal set of lentiviral genes required to generate the virion structural proteins and packaging functions.
- The vesicular stomatitis virus G-protein envelope vector, which provides the heterologous envelope for pseudotyping.
- The shRNA transfer vector, which contains the sequence of interest as well as the cis acting sequences necessary for RNA production and packaging.
The Lentiviral Packaging Mix contains the first two components; it is designed to be co-transfected along with a compatible lentiviral transfer vector in order to create high-titer pseudo-typed lentiviral particles used for downstream transduction applications.
Application
MISSION® Lentiviral Packaging Mix has been used to incubate plasmids before addition to human embryonic kidney cells 293 expressing the large T antigen (293T cells) and to pack lentivirus into 293T cells.
Other Notes
Lentiviral particles are produced using a third-generation packaging system, which has many features that lead to enhanced biosafety. Recombinant lentiviruses produced with the MISSION Lentiviral Packaging Mix have not been shown to produce replication competent viral particles because of designed safety features. Users should consult and observe their own institutional guidelines before working with such viral systems.
Legal Information
Use of this product is subject to one or more license agreements. For details, please see http://sigmaaldrich.com/missionlicense .
MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Regulatory Information
新产品
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Wenwen Chien et al.
Journal of Cancer, 9(24), 4762-4773 (2018-12-28)
This study is an unbiased genomic screen to obtain functional targets for increased effectiveness of dasatinib in pancreatic cancer. Dasatinib, a multi-targeted tyrosine kinase inhibitor, is used in clinical trials for treatment of pancreatic cancer; however, intrinsic and acquired resistance
Heterogenous ribonucleoprotein A18 (hnRNP A18) promotes tumor growth by increasing protein translation of selected transcripts in cancer cells.
Chang ET
Oncotarget, 7(9), 10578-10593 (2016)
Deniz Simsek et al.
PLoS genetics, 7(6), e1002080-e1002080 (2011-06-10)
Nonhomologous end-joining (NHEJ) is the primary DNA repair pathway thought to underlie chromosomal translocations and other genomic rearrangements in somatic cells. The canonical NHEJ pathway, including DNA ligase IV (Lig4), suppresses genomic instability and chromosomal translocations, leading to the notion
Helen He et al.
Journal of biomarkers, 2016, 1274603-1274603 (2016-06-02)
Objective. Use of tyramide signal amplification (TSA) to detect autophagy biomarkers in formalin fixed and paraffin embedded (FFPE) xenograft tissue. Materials and Methods. Autophagy marker regulation was studied in xenograft tissues using Amp HQ IHC and standard IHC methods. Results.
SNAI1-Driven Sequential EMT Changes Attributed by Selective Chromatin Enrichment of RAD21 and GRHL2.
Vignesh Sundararajan et al.
Cancers, 12(5) (2020-05-07)
Over two decades of research on cancer-associated epithelial-mesenchymal transition (EMT) led us to ascertain the occurrence of transitional intermediate states (collectively referred to as the EMT spectrum). Among the molecular factors that drive EMT, SNAI1 plays an indispensable role in
Articles
MISSION shRNA reduce the expression of specific target genes by targeting the specific mRNA therefore reducing the corresponding protein expression.
When shRNA is delivered using lentiviral vectors, the sequence encoding the shRNA is integrated into the genome and the knockdown effect is passed on to daughter cells, continuing gene silencing.
Protocols
Preparation of the Lentiviral Transduction Particles Using Packaging Plasmid Mix
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service